CA-I2C
22.9.2021 12:14:05 CEST | Business Wire | Press release
i2c Inc. , a leading provider of digital payment and banking technology, today disclosed what it sees as key opportunities for growth in the UK and European markets, highlighting digital first, B2B commercial payments, cryptocurrency and credit as high-demand areas in which it is favorably positioned to compete.
“In the past 18 months, we’ve seen increased opportunities as well as validation and acceptance of our offering in initiatives where these criteria and related use cases play heavily to customers’ requirements,” said Jonathan Vaux, general manager for UK and EU at i2c. He also noted that the driving forces appear to be a combination of continued bank digitization, a surge in payments and financial innovation in the commercial space, heightened competition among crypto players to achieve faster innovation cycles and market expansion, and broad interest in reconstructing credit as an embedded feature.
According to the company, its platform features distinct characteristics that UK and European partners find compelling as they assess certain use case conditions, for example, span of product and geographies.
Among these elements is i2c’s membership in Mastercard’s Fintech Express Program, which allows the region’s issuers to tap into the speed and security of Mastercard’s global network.
“During a time of accelerated digital shift, consumers are seeking digital financial services. We are pleased to welcome i2c to our Fintech Express program. It will enable their customers easy access to the Mastercard platform, which hosts key products and programs in one place," said Jason Lane, Executive Vice President, Market Development, Europe, Mastercard.
Vaux also shared that the current pace of innovation and level of competition in digital first, commercial payments and cryptocurrency is affecting issuers in similar ways, be they UK or European mid-tier banks moving to instant issuance, fintechs addressing unmet needs in the commercial market, or corporates enabling their own modern payment capabilities.
“In Europe we initially saw a high demand from fintechs, such as neo-banks, to leverage pre-existing prepaid platforms and capabilities to get digital offerings to market locally and as quickly as possible,” Vaux said. “However, as the market has matured, we are now seeing increasing demand for extension into new capabilities, whether that be credit, debit, commercial or crypto, a much greater need to support global expansion, and much higher expectations of configurability to support tailored propositions that meet the needs of emerging segments.”
Among those partnering with i2c in Europe to transform the payments landscape, is UK-based EedenBull , a leading fintech specializing in B2B commercial payments technology.
“The payments world is evolving very rapidly, especially in the commercial banking sector. We’re launching new features and functionalities every 2 weeks, and have partnered with over 60 banks worldwide,” shared Nicki Bull Bisgaard, CEO of EedenBull. Adding, “i2c’s platform has provided the flexibility, reliability, and security we needed to expand into a truly global company and continues to enable our impact across the B2B space.”
According to i2c, the region which has been at the cutting-edge of initiatives such as open banking and fintech, is now seeing increasing sophistication in client requirements and expectations of their processing partnerships. To this end, the company said it had deepened its alliances with global partners, such as the Fintech Express partnership with Mastercard, as well as its local partnerships with BIN sponsors and clients in the UK and Europe.
About i2c Inc.
i2c is a global provider of highly-configurable payment and banking solutions. Using i2c's proprietary "building block" technology, clients can easily create and manage a comprehensive set of solutions for credit, debit, prepaid, lending and more, quickly and cost-effectively. i2c delivers unparalleled flexibility, agility, security and reliability from a single global SaaS platform. Founded in 2001, and headquartered in Silicon Valley, i2c's next-generation technology supports millions of users in more than 200 countries/ territories and across all time zones. For more information, visit www.i2cinc.com and follow us at @i2cinc .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005426/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom